PacBio (PACB) announces its critical role in a study to be published in Nature Genetics. The study, titled Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition, showcases how researchers leveraged PacBio’s advanced sequencing solutions, including the synchronized Fiber-seq and Kinnex multiomic approach, to uncover the genetic and molecular basis of a rare and complex Mendelian condition.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Largest borrow rate increases among liquid names
- PacBio announces GIFS at USask as first Revio PacBio CSP in Canada
- PacBio, Radboud UMC announces study results using HiFi long read sequencing
- PacBio reports Q4 preliminary revenue $39.2M, consensus $40.63M
- PacBio, Intus Bio collaborate for launch of GutID
